The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.

Is there still a prominent role for primary prevention implantable cardioverter defibrillators (ICDs) in heart failure patients? From ejection fraction to QRS duration -- what criteria do you and your colleagues employ the most to determine candidates for primary prevention ICD therapy?

We know treatment gaps exist. What are they and what are you doing in your practice to improve the use of evidence-based implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) device therapies in patients with heart failure (HF)? See what your colleagues are doing in their practices.